TheraRadar

Pharma Intelligence, Simplified

Landscape → Oncology

Cervical Cancer

439 clinical trials

274 active
/
439 total (since 2015)
96
Phase 1 Active
166 total
177
Phase 2 Active
259 total
44
Phase 3 Active
72 total
9
Phase 4 Active
14 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
AstraZeneca 4 2 0
Shanghai Bovax Biotechnology Co., Ltd. 3 3 1
Merck 3 3 0
NGM Biopharmaceuticals, Inc 3 0 0
Akeso 2 3 0
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 2 0 1
Eli Lilly 2 0 1
Jiangsu HengRui Medicine Co., Ltd. 2 1 0
SystImmune Inc. 2 0 0
Sichuan Baili Pharmaceutical Co., Ltd. 2 0 0
Radiopharm Theranostics, Ltd 2 0 0
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 2 0 0
Shanghai Shengdi Pharmaceutical Co., Ltd 2 0 0
OncoC4, Inc. 2 0 0
Evopoint Biosciences Inc. 2 0 0
NCT07061977 RECRUITING
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
National Cancer Institute (NCI) n=336
NCT02466971 ACTIVE NOT RECRUITING
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
National Cancer Institute (NCI) n=450
NCT06459180 RECRUITING
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Merck Sharp & Dohme LLC n=686
NCT07216703 RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Merck Sharp & Dohme LLC n=1,023
NCT06079671 RECRUITING
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
AstraZeneca n=800
NCT05581121 RECRUITING
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Institut Claudius Regaud n=510
NCT07418749 NOT YET RECRUITING
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=398
NCT07400536 NOT YET RECRUITING
A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology n=378
NCT07392060 NOT YET RECRUITING
A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment
Shanghai Jiatan Pharmatech Co., Ltd n=440
NCT07298642 RECRUITING
Extended-field Proton Therapy for Cervical Cancer
National Taiwan University Hospital n=44
NCT06851663 RECRUITING
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital n=400
NCT04537156 ACTIVE NOT RECRUITING
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Xiamen University n=9,327
NCT04982237 ACTIVE NOT RECRUITING
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Akeso n=445
NCT07230626 NOT YET RECRUITING
SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. n=412
NCT07168200 RECRUITING
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd n=720
NCT07177716 NOT YET RECRUITING
Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer
L & L Bio Co., Ltd., Ningbo, China n=120
NCT04906993 ACTIVE NOT RECRUITING
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd. n=443
NCT05056402 ACTIVE NOT RECRUITING
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
Xiamen University n=1,382
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT06156514 RECRUITING
Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer
National Institute of Cancerología n=140
NCT06459687 RECRUITING
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
Lee's Pharmaceutical Limited n=440
NCT06641635 RECRUITING
Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
Peking Union Medical College Hospital n=440
NCT06870565 NOT YET RECRUITING
Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma
Women's Hospital School Of Medicine Zhejiang University n=238
NCT06123884 RECRUITING
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Bio-Thera Solutions n=526
NCT06755515 ENROLLING BY INVITATION
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Shandong New Time Pharmaceutical Co., LTD n=510
NCT06692166 RECRUITING
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Mabwell (Shanghai) Bioscience Co., Ltd. n=420
NCT04723875 ACTIVE NOT RECRUITING
Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline
Huazhong University of Science and Technology n=306
NCT06288373 RECRUITING
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Tongji Hospital n=440
NCT05235516 ACTIVE NOT RECRUITING
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
Akeso n=636
NCT05764044 RECRUITING
Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer
Hospital do Coracao n=365
NCT03755739 RECRUITING
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=200
NCT04422366 RECRUITING
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd. n=8,000
NCT05027776 RECRUITING
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd. n=1,348
NCT04895020 RECRUITING
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd. n=1,200
NCT06333821 NOT YET RECRUITING
A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma
Biotech Pharmaceutical Co., Ltd. n=460
NCT05173272 RECRUITING
Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer
Sichuan Cancer Hospital and Research Institute n=286
NCT03534713 RECRUITING
Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread
University Hospital, Toulouse n=310
NCT04989647 RECRUITING
Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy
The Central and Eastern European Gynecologic Oncology Group n=514
NCT05798819 NOT YET RECRUITING
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Guangzhou Gloria Biosciences Co., Ltd. n=424
NCT05715840 NOT YET RECRUITING
Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=368
NCT05277688 RECRUITING
Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients
Ruijin Hospital n=340
NCT05367206 RECRUITING
Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial
Sun Yat-sen University n=280
NCT04974346 RECRUITING
Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer
Zhejiang Cancer Hospital n=455
NCT04733820 RECRUITING
Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery
Huazhong University of Science and Technology n=340
NCT04697628 COMPLETED
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Seagen, a wholly owned subsidiary of Pfizer n=502
NCT03635567 COMPLETED
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
Merck Sharp & Dohme LLC n=617
NCT06866951 WITHDRAWN
A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial
Women's Hospital School Of Medicine Zhejiang University
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT06007586 COMPLETED
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Sichuan Cancer Hospital and Research Institute n=143
NCT03728881 COMPLETED
Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial
National Cancer Institute (NCI) n=1,240
NCT02446652 WITHDRAWN
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
National Institute of Cancerología
NCT05179239 TERMINATED
A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=31
NCT03257267 COMPLETED
Study of Cemiplimab in Adults With Cervical Cancer
Regeneron Pharmaceuticals n=608
NCT04508309 COMPLETED
Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls
PATH n=1,025
NCT03493542 COMPLETED
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
Merck Sharp & Dohme LLC n=766
NCT03308591 COMPLETED
Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients
Huazhong University of Science and Technology n=774
NCT03830866 COMPLETED
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
AstraZeneca n=770
NCT05564286 COMPLETED
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
Shantou University Medical College n=116
NCT04864782 TERMINATED
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
Qilu Pharmaceutical Co., Ltd. n=46
NCT05372016 COMPLETED
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd. n=1,200
NCT05584332 TERMINATED
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd. n=3,131
NCT04782895 COMPLETED
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
Xiamen University n=488
NCT02853604 TERMINATED
Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer
Advaxis, Inc. n=110
NCT04943627 WITHDRAWN
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
NCT03476018 COMPLETED
Trial to Optimally Show the Pharmacological Action of Z-100
Zeria Pharmaceutical n=72
NCT05384366 COMPLETED
Neoadjuvant Chemotherapy in Cervical Cancer
Banaras Hindu University n=33
NCT04806945 WITHDRAWN
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
Shanghai Henlius Biotech
NCT04425291 COMPLETED
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd. n=1,680
NCT03413579 COMPLETED
Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom
El Kendi Pharmaceuticals Manufacturing Company n=37
NCT04237090 COMPLETED
Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel
Ciusss de L'Est de l'Île de Montréal n=27
NCT03158220 COMPLETED
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Merck Sharp & Dohme LLC n=1,212
NCT02562508 COMPLETED
A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
Jun Zhang n=979

Data: ClinicalTrials.gov